*From the Authors*:

We appreciate the interest in our recent manuscript ([@bib1]) describing issues in noninferiority trials of latent tuberculosis infection (LTBI) treatments. However, we believe that Swindells and colleagues are misinterpreting one of the fundamental points in the manuscript. Our model did not assume that people with HIV infection and a negative tuberculin skin test (TST) or IFN-γ release assay (IGRA) are not at risk for tuberculosis and do not benefit from LTBI treatment. On the contrary, we used reasonable estimates of test sensitivity and specificity from the best available evidence ([@bib2], [@bib3]) combined with a wide range of underlying population prevalence estimates to calculate the prevalence of LTBI among persons with negative tests, and then assumed that all of those persons were at risk to progress to active tuberculosis. For example, if the prevalence of LTBI in a population was 30% and we use the assumptions of 60% sensitivity and 70% specificity for the TST, then the prevalence of LTBI among persons with negative TST (i.e., false-negative TST) recruited from this population would be (0.3) × (0.4) ÷ (0.3 × 0.4 + 0.7 × 0.7) = 19.6%. Our model assumed that persons with LTBI (i.e., persons with true-positive TST/IGRA or false-negative TST/IGRA) were at risk to progress to active tuberculosis, but that persons without LTBI (i.e., persons with false-positive TST/IGRA results and persons with true-negative TST/IGRA results) were not at risk to progress to active tuberculosis.

Understanding this point is fundamental to correct interpretation of our model, which explores the implications of the principle that recruiting on the basis of negative test results (TST/IGRA) reduces the prevalence of LTBI in the study population below the prevalence in the general population from which participants were recruited. This reduction, in turn, diminishes the number of participants at risk for the outcome of interest (active tuberculosis in this case) and results in fewer outcomes than might otherwise have been expected. Because the test performance does not depend on allocated treatment, test results should have no impact on the relative magnitude of event rates between arms, so the consistency in results between IGRA-negative and IGRA-positive participants in TEMPRANO ([@bib4]) is entirely compatible with our model. However, in the setting of a noninferiority trial with an absolute noninferiority margin, fewer outcomes in both arms translate to lower absolute event rates, lower absolute differences in event rates, and a higher chance of falsely declaring an arm with low efficacy noninferior. In the case of BRIEF TB (Brief Rifapentine-Isoniazid Efficacy for Tuberculosis Prevention) ([@bib5]), although the subgroup analysis of participants with a positive test met the prespecified absolute noninferiority margin, the low observed event rates in the trial and in this subgroup mean that one can only say with 95% confidence that the incidence rate ratio among persons with positive TST/IGRA in the 1-month arm was somewhere between 35% and 241% of that observed in the 9-month arm. With such a wide range of possible relative efficacies, a well-powered, well-designed study to confirm or refute the efficacy of the BRIEF-TB regimen using tests with high specificity to recruit participants would be a necessary step in the right direction.
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